Q-omics provides the consensus-scored HARS1 profile across patient tissues and cancer cell-line models. HARS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HARS1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HARS1 RNA expression shows 18,420 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KIRC, and KIRP as cancer lineages where HARS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HARS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HARS1 survival associations across molecular data types. HARS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HARS1 RNA expression–survival associations across cancer types. High HARS1 expression shows unfavorable associations in LUAD, HNSC, KICH, LIHC and ESCA, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HARS1 RNA expression.
This table summarizes HARS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HARS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HARS1 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, LUAD and HNSC. The KIRC box plot shows higher HARS1 RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with HARS1 in patient tissues and cancer cell lines. In patient samples, HARS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, HARS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
